animalsareunsuitableforhumanconsumption.Further,HormoneReplacements
Therapiesusingsyntheticandotherunnaturalmeanshavebeenlinkedtoriskssuch
as:
AnotherimportantareatodiscussistherisksofHRT.Thereisno
evidencethatHRTatpost-menopausaldosesincreaseshyperten-
sionorclottingabnormalities.Commonpossibleside-effectsin-
cludewithdrawalbleedingwithcyclicdosing,spottingduringthe
firstthreetosixmonthswithcombinedcontinuoustherapy,mas-
talgia,edema,abdominalbloating,andincreaseinthesizeofuter-
ineleiomyomata.Rarely,symptomsofanxietyanddepressioncan
beworsenedwithinitiationofHRT.Althoughthereisnoincrease
inasymptomaticgallstones,a2.7-foldincrease(3.4%to9.8%)in
cholecystectomyhasbeennoted.OtherrisksincludeBreastCan-
cerand Endometrial Cancer. 197
ItwasreportedinthemedicaljournalTheLancet,thatJapanesewomensuffered
fromfewersymptomsofmenopausethanWesternwomen.Itisthoughtthatthisis
duetothedietoftheJapanesewomen,whichincludesphytoestrogens,estrogens
fromplants,suchassoybeans,tofu,miso,flaxseeds,pomegranates,anddates. 198
Therefore,itisonceagainevidentthatnaturalsourcesratherthanartificiallypro-
ducedremediesaremoreeffectiveandsafeforthepromotionofhealthymiddleage
in women as well as men.
Other studies reported by news agencies include:
CNN.com
Study: Estrogen increases ovarian cancerrisk(20-Mar-01)
Women who use supplemental estrogen after menopause for10 years or more double their risk of
dying from ovarian cancer, according to a study released Tuesday. This increased risk persists up
to 29 years after a woman stops using the hormone therapy.
Hormone replacement therapy study halted(09-Jul-02)
In a move that may affect millions of women, U.S. government scientists Tuesday stopped a ma-
jor study of hormone replacement therapy on the risks and benefits of combined estrogen and
progestin in healthy menopausal women, citing an increased risk of invasive breast cancer.
FDA to reassess hormone replacementrisks(14-Aug-02)